Virax Biolabs Group Ltd. Class A (VRAX)
NASDAQ:VRAX
US Market
Holding VRAX?
Track your performance easily

Virax Biolabs Group Ltd. Class A (VRAX) Financial Statements

33 Followers

Virax Biolabs Group Ltd. Class A Financial Overview

Virax Biolabs Group Ltd. Class A's market cap is currently ―. The company's EPS TTM is $-4.22; its P/E ratio is -0.27; Virax Biolabs Group Ltd. Class A is scheduled to report earnings on February 2, 2023, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Mar 23Sep 22Mar 22Sep 21Mar 21
Income Statement-
Total Revenue-----
Gross Profit-----
EBIT-----
EBITDA-----
Net Income Common Stockholders-----
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 9.35M$ 4.57M$ 21.76K$ 11.68K$ 17.62K
Total Assets$ 9.81M$ 5.30M$ 48.71K$ 43.03K$ 39.62K
Total Debt$ 146.25K$ 390.00K$ 0.00$ 100.00K$ 0.00
Net Debt$ -9.21M$ -4.18M$ -21.76K$ 88.32K$ -17.62K
Total Liabilities$ 909.96K$ 1.14M$ 1.25M$ 1.05M$ 871.43K
Stockholders Equity$ 9.12M$ 4.39M$ -974.58K$ -798.87K$ -650.68K
Cash Flow-
Free Cash Flow-----
Operating Cash Flow-----
Investing Cash Flow-----
Financing Cash Flow-----
Currency in USD

Virax Biolabs Group Ltd. Class A Earnings and Revenue History

Virax Biolabs Group Ltd. Class A Debt to Assets

Virax Biolabs Group Ltd. Class A Cash Flow

Virax Biolabs Group Ltd. Class A Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis